1
|
Manchuri KM, Shaik MA, Gopireddy VSR, Naziya Sultana, Gogineni S. Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices. Chem Res Toxicol 2024. [PMID: 39158368 DOI: 10.1021/acs.chemrestox.4c00234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/20/2024]
Abstract
Since 2018, N-nitrosamine impurities have become a widespread concern in the global regulatory landscape of pharmaceutical products. This concern arises due to their potential for contamination, toxicity, carcinogenicity, and mutagenicity and their presence in many active pharmaceutical ingredients, drug products, and other matrices. N-Nitrosamine impurities in humans can lead to severe chemical toxicity effects. These include carcinogenic effects, metabolic disruptions, reproductive harm, liver diseases, obesity, DNA damage, cell death, chromosomal alterations, birth defects, and pregnancy loss. They are particularly known to cause cancer (tumors) in various organs and tissues such as the liver, lungs, nasal cavity, esophagus, pancreas, stomach, urinary bladder, colon, kidneys, and central nervous system. Additionally, N-nitrosamine impurities may contribute to the development of Alzheimer's and Parkinson's diseases and type-2 diabetes. Therefore, it is very important to control or avoid them by enhancing effective analytical methodologies using cutting-edge analytical techniques such as LC-MS, GC-MS, CE-MS, SFC, etc. Moreover, these analytical methods need to be sensitive and selective with suitable precision and accuracy, so that the actual amounts of N-nitrosamine impurities can be detected and quantified appropriately in drugs. Regulatory agencies such as the US FDA, EMA, ICH, WHO, etc. need to focus more on the hazards of N-nitrosamine impurities by providing guidance and regular updates to drug manufacturers and applicants. Similarly, drug manufacturers should be more vigilant to avoid nitrosating agents and secondary amines during the manufacturing processes. Numerous review articles have been published recently by various researchers, focusing on N-nitrosamine impurities found in previously notified products, including sartans, metformin, and ranitidine. These impurities have also been detected in a wide range of other products. Consequently, this review aims to concentrate on products recently reported to contain N-nitrosamine impurities. These products include rifampicin, champix, famotidine, nizatidine, atorvastatin, bumetanide, itraconazole, diovan, enalapril, propranolol, lisinopril, duloxetine, rivaroxaban, pioglitazones, glifizones, cilostazol, and sunitinib.
Collapse
Affiliation(s)
- Krishna Moorthy Manchuri
- Department of Chemistry, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, Andhra Pradesh 515002, India
| | - Mahammad Ali Shaik
- Department of Chemistry, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, Andhra Pradesh 515002, India
| | - Venkata Subba Reddy Gopireddy
- Department of Chemistry, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, Andhra Pradesh 515002, India
| | - Naziya Sultana
- Analytical Research and Development, IPDO, Dr. Reddy's Laboratories Limited, Hyderabad 500090, India
| | - Sreenivasarao Gogineni
- Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh 522510, India
| |
Collapse
|
2
|
Planinšek Parfant T, Skube T, Roškar R. A robust analytical method for simultaneous quantification of 13 low-molecular-weight N-Nitrosamines in various pharmaceuticals based on solid phase extraction and liquid chromatography coupled to high-resolution mass spectrometry. Eur J Pharm Sci 2024; 192:106633. [PMID: 37951317 DOI: 10.1016/j.ejps.2023.106633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 11/02/2023] [Accepted: 11/06/2023] [Indexed: 11/13/2023]
Abstract
Recently, the potentially highly carcinogenic N-nitrosamines (NAs) have become the focus of pharmaceutical regulatory authorities, the pharmaceutical industry and researchers because trace amounts have been detected in some drug products (DPs), resulting in drug supply shortages. In the absence of sufficient analytical methods for the determination of multiple regulated low-molecular-weight NAs in various DPs, a robust, selective, sensitive and accurate method based on sample preparation by solid phase extraction, followed by liquid chromatography high-resolution mass spectrometry for the simultaneous analysis of 13 regulated low-molecular-weight NAs was developed. The best results for the cleanup were obtained using Strata X-C SPE cartridge. The proposed method was successfully validated according to the USP general chapter 〈1469〉, demonstrating its excellent linearity, accuracy and precision in wide analytical ranges, adjusted to NAs acceptable intake limits. The achieved limits of quantitation correspond to 30 % or less of the acceptable intake limits. The developed analytical method was applied to 16 commercially available DPs containing one to three active pharmaceutical ingredients with different physicochemical properties. Only N-Nitrosodimethylamine was detected in DPs containing ranitidine at levels exceeding the regulatory AI limits by 37.6 - 57.4-fold. In addition, the robustness of the method was confirmed on a considerable number of DPs containing different active ingredients, demonstrating the suitability of the analytical method for routine quality control of different DPs, thus mitigate the risk to human health.
Collapse
Affiliation(s)
| | - Taja Skube
- University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia
| | - Robert Roškar
- University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
| |
Collapse
|
3
|
Witkowska AB, Wołczyńska A, Lis-Cieplak A, Stolarczyk EU. Development and Validation of LC-MS/MS Method for the Determination of 1-Methyl-4-Nitrosopiperazine (MNP) in Multicomponent Products with Rifampicin-Analytical Challenges and Degradation Studies. Molecules 2023; 28:7405. [PMID: 37959824 PMCID: PMC10648194 DOI: 10.3390/molecules28217405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 10/27/2023] [Accepted: 10/30/2023] [Indexed: 11/15/2023] Open
Abstract
Rifampicin is an essential medicine for treating and preventing tuberculosis (TB). TB is a life-threatening infectious disease and its prevention and treatment are public health imperatives. In the time of a global crisis of nitrosamine contamination of medicinal products, patient safety and a reduction in the number of drug recalls at the same time are crucial. In this work, the LC-MS/MS method was developed for the determination of the 1-methyl-4-nitrosospiperazine (MNP), a genotoxic nitrosamine impurity in various products containing rifampicin at a 5.0 ppm limit level according to Food and Drug Administration (FDA). Extraction with neutralization was necessary due to the matrix and solvent effect associated with the complexity of the rifampicin product. The developed method was validated in accordance with regulatory guidelines. Specificity, accuracy, precision, limit of detection, and limit of quantification parameters were evaluated. The recovery of the MNP was 100.38 ± 3.24% and the intermediate precision was 2.52%. The contamination of MNP in Rifampicin originates in the manufacturing process of the drug. Furthermore, the results of the forced degradation experiments show that the formation of MNP is possible by two mechanisms: through degradation of rifampicin and the oxidation of 1-amino-4-methyl-piperazine. This article points out that it is necessary to monitor and describe degradation products and the mechanism of degradation of potentially affected active pharmaceutical ingredient (API) with respect to the formation of nitrosamines during stress testing, as it was done in the following work for rifampicin in multicomponent products.
Collapse
Affiliation(s)
- Anna B. Witkowska
- Spectrometric Methods Department, National Medicines Institute, 30/34 Chełmska, 00-725 Warsaw, Poland; (A.B.W.); (A.W.); (A.L.-C.)
- Department of Drug Chemistry, Doctoral School, Medical University of Warsaw, 61 Żwirki i Wigury, 02-091 Warsaw, Poland
| | - Aleksandra Wołczyńska
- Spectrometric Methods Department, National Medicines Institute, 30/34 Chełmska, 00-725 Warsaw, Poland; (A.B.W.); (A.W.); (A.L.-C.)
| | - Agnieszka Lis-Cieplak
- Spectrometric Methods Department, National Medicines Institute, 30/34 Chełmska, 00-725 Warsaw, Poland; (A.B.W.); (A.W.); (A.L.-C.)
| | - Elżbieta U. Stolarczyk
- Spectrometric Methods Department, National Medicines Institute, 30/34 Chełmska, 00-725 Warsaw, Poland; (A.B.W.); (A.W.); (A.L.-C.)
| |
Collapse
|
4
|
Plachká K, Pilařová V, Horáček O, Gazárková T, Vlčková HK, Kučera R, Nováková L. Columns in analytical-scale supercritical fluid chromatography: From traditional to unconventional chemistries. J Sep Sci 2023; 46:e2300431. [PMID: 37568246 DOI: 10.1002/jssc.202300431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/31/2023] [Accepted: 08/01/2023] [Indexed: 08/13/2023]
Abstract
Within this review, we thoroughly explored supercritical fluid chromatography (SFC) columns used across > 3000 papers published from the first study carried out under SFC conditions in 1962 to the end of 2022. We focused on the open tubular capillary, packed capillary, and packed columns, their chemistries, dimensions, and trends in used stationary phases with correlation to their specific interactions, advantages, drawbacks, used instrumentation, and application field. Since the 1990s, packed columns with liquid chromatography and SFC-dedicated stationary phases for chiral and achiral separation are predominantly used. These stationary phases are based on silica support modified with a wide range of chemical moieties. Moreover, numerous unconventional stationary phases were evaluated, including porous graphitic carbon, titania, zirconia, alumina, liquid crystals, and ionic liquids. The applications of unconventional stationary phases are described in detail as they bring essential findings required for further development of the supercritical fluid chromatography technique.
Collapse
Affiliation(s)
- Kateřina Plachká
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Veronika Pilařová
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Ondřej Horáček
- Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Taťána Gazárková
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Hana Kočová Vlčková
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Radim Kučera
- Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Lucie Nováková
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| |
Collapse
|
5
|
Patel R, Purohit S, Solanki R, Khunt D, Patel C, Patel R, Parikh S. Development and validation of an analytical method for trace-level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed-dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2023; 37:e9488. [PMID: 36740827 DOI: 10.1002/rcm.9488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 01/22/2023] [Accepted: 02/02/2023] [Indexed: 06/18/2023]
Abstract
RATIONALE Since June 2018, globally large numbers of pharmaceuticals have been recalled due to the unexpected presence of nitrosamines. Beginning with the class of pharmaceuticals known as sartans, subsequent lines of inquiry included antidiabetic medicines, antihistamines, and antibiotics. A critical review of the U.S. Food and Drug Administration database reveals that the highest number of products recall due to the presence of unacceptable levels of nitrosamines were losartan potassium drug products and their coformulations with other drug substances. The problem can be mainly attributed to naively adopted approval revisions and the lack of sufficient current analytical technologies to detect those contaminants in time. In this work, we developed a specific, selective, accurate, precise, and robust ultra-performance liquid chromatography-triple quadrupole-mass spectrometry (UPLC-TQ-MS/MS) method for the estimation of eight genotoxic nitrosamine impurities in losartan and hydrochlorothiazide (HCTZ) tablets, which is the only fixed-dosage combination approved by the USFDA to treat hypertension. METHODS All the nitrosamine impurities along with the drug substances were separated using an Agilent Pursuit XRs Ultra diphenyl column (150 × 2.0 mm, 2.8 μm) with mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in methanol) at a flow rate of 0.4 ml/min using the gradient elution program. The proposed method was validated per ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Q2 (R1) guidelines to ensure the method is suitable for its intended purpose. RESULTS Limit of detection and limit of quantification were obtained in the range of 0.25-0.5 ng/mL, which was very low compared to levels specified by the USFDA, European Medicines Agency (EMA), and other regulatory authorities that ensure the sensitivity of the method in its entire life cycle. CONCLUSIONS The developed method can be incorporated into an official monograph and applied for routine quality control analysis of losartan and HCTZ fixed-dose combination tablets.
Collapse
Affiliation(s)
- Ravi Patel
- Department of Quality Assurance, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India
| | - Sanjay Purohit
- Department of Quality Assurance, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India
| | - Ravisinh Solanki
- Department of Quality Assurance, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India
| | - Dignesh Khunt
- Department of Pharmaceutics, Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, India
| | - Chhaganbhai Patel
- Department of Medicinal Chemistry, Shri Sarvajanik Pharmacy College, Mehsana, India
| | - Rucha Patel
- Regulatory Affairs Division, JAMP INDIA Pharmaceutical Pvt. Ltd., Ahmedabad, India
| | - Shalin Parikh
- Analytical Development Division, Senores Pharmaceuticals, Ahmedabad, India
| |
Collapse
|
6
|
Yin M, Hu Y, Fan H, Wang Q, Wang M, Wang W, Shi C. Method for trace determination of N-nitrosamines impurities in metronidazole benzoate using high-performance liquid chromatography coupled with atmospheric-pressure chemical ionization tandem mass spectrometry. J Sep Sci 2023; 46:e2200225. [PMID: 36562102 DOI: 10.1002/jssc.202200225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 12/19/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022]
Abstract
Genotoxic impurity control has been a great concern in the pharmaceutical industry since the recall of the large round of sartans worldwide in 2018. In these sartans, N-nitrosamines were the main contaminants in active pharmaceutical ingredients and formulations. Numerous analytical methods have been developed to detect N-nitrosamines in food, drugs, and environmental samples. In this study, a sensitive method is developed for the trace determination of N-nitrosamine impurities in metronidazole benzoate pharmaceuticals using high-performance liquid chromatography/atmospheric-pressure chemical ionization tandem mass spectrometry in the multiple reaction monitoring mode. The method was validated regarding system suitability, selectivity, linearity, accuracy, precision, sensitivity, solution stability, and robustness. The method showed good linearity with R2 ≥ 0.999 and FMandel < Ftab(95%) ranging from 0.33 to 8.00 ng/ml. The low limits of detection of N-nitrosamines were in the range of 0.22-0.80 ng/ml (0.0014-0.0050 ppm). The low limits of quantification were in the range of 0.33-1.20 ng/ml (0.0021-0.0075 ppm), which were lower than the acceptable limits in metronidazole benzoate pharmaceuticals and indicated the high sensitivity of the method. The recoveries of N-nitrosamines ranged from 84% to 97%. Thus, this method exhibits good selectivity, sensitivity, and accuracy. Moreover, it is a simple, convenient, and scientific strategy for detecting N-nitrosamine impurities in pharmaceuticals to support the development of the pharmaceutical industry.
Collapse
Affiliation(s)
- Mingxing Yin
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
| | - Yinuo Hu
- Hubei Hongyuan Pharmaceutical Technology Ltd., Huanggang, P. R. China
| | - Huajun Fan
- ICAS Testing Technology Service (Shanghai) Ltd., Shanghai, P. R. China
| | - Qiulan Wang
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
| | - Mengdie Wang
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
| | - Wenqing Wang
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
| | - Chunyang Shi
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China
| |
Collapse
|
7
|
A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products. Regul Toxicol Pharmacol 2023; 139:105355. [PMID: 36792049 DOI: 10.1016/j.yrtph.2023.105355] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 01/22/2023] [Accepted: 02/06/2023] [Indexed: 02/15/2023]
Abstract
N-nitrosamines are carcinogenic impurities most commonly found in groundwater, treated water, foods, beverages and consumer products. The recent discovery of N-nitrosamines in pharmaceutical products and subsequent recalls pose a significant health risk to patients. Initial investigation by the regulatory agency identified Active Pharmaceutical Ingredients (API) as a source of contamination. However, N-nitrosamine formation during API synthesis is a consequence of numerous factors like chemistry selection for synthesis, contaminated solvents and water. Furthermore, apart from API, N-nitrosamines have also been found to embed in the final product due to degradation during formulation processing or storage through contaminated excipients and printing inks. The landscape of N-nitrosamine contamination of pharmaceutical products is very complex and needs a comprehensive compilation of sources responsible for N-nitrosamine contamination of pharmaceutical products. Therefore, this review aims to extensively compile all the reported and plausible sources of nitrosamine impurities in pharmaceutical products. The topics like risk assessment and quantitative strategies to estimate nitrosamines in pharmaceutical products are out of the scope of this review.
Collapse
|
8
|
Schmidtsdorff S, Neumann J, Schmidt AH, Parr MK. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome? Arch Pharm (Weinheim) 2023; 356:e2200484. [PMID: 36461687 DOI: 10.1002/ardp.202200484] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 10/16/2022] [Accepted: 10/20/2022] [Indexed: 12/04/2022]
Abstract
Various drug samples (N = 249; drug substances, tablets, capsules, solutions, crèmes, and more) from the European pharmaceutical market were collected since 2019 and analyzed for 16 nitrosamines (NAs). In 2.0% of the cases, NAs were detected. These findings included four active pharmaceutical ingredients already known for potential NA contamination: losartan (N-nitrosodimethylamine [NDMA] and N-nitrosodiethylamine, simultaneously), valsartan (NDMA), metformin (NDMA) and ranitidine (NDMA). The fifth new finding, which has not been reported yet, discovered contamination of a molsidomine tablet sample with N-nitrosomorpholine (NMor). The tablet contained 144% of the toxicological allowable intake for NMor. NMor was included in our screening from the beginning and is currently the focus of regulatory authorities, but was added to the guidelines only last year. Thus, it may not have been the focus of regulatory investigations for too long. Our results indicate that the majority of drug products in the market are nonhazardous in terms of patient safety and drug purity. Unfortunately, the list of individual affected products keeps growing constantly and new NA cases, such as molsidomine or nitrosated drug substances (nitrosamine drug substance-related impurities [NDSRI]), continue to emerge. We therefore expect nitrosamine screenings to remain a high priority.
Collapse
Affiliation(s)
- Sebastian Schmidtsdorff
- Chromicent GmbH, Berlin, Germany.,Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | - Jonas Neumann
- Chromicent GmbH, Berlin, Germany.,Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | | | - Maria K Parr
- Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| |
Collapse
|
9
|
Holzgrabe U. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned? J Pharm Sci 2023; 112:1210-1215. [PMID: 36720391 DOI: 10.1016/j.xphs.2023.01.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 01/04/2023] [Accepted: 01/23/2023] [Indexed: 01/30/2023]
Abstract
The occurrence of N-nitrosodialkylamines in active pharmaceutical ingredients (APIs) and drug products in the last years was a kind of eye opener with regard to quality of drugs. We became aware of the fact that quality control tests described in the international pharmacopoeias might not be sufficient. The N-nitrosodialkylamines found were neither so-called (structurally) related substances, nor residual solvents or heavy metals; hence they were not limited by a compendial test, but by the ICH guideline M7 of mutagenic impurities. Additionally, nitrosamine drug-substance-related impurities (NDSRIs) were detected, mostly within the process of risk assessment required by regulatory authorities. Here, the APIs containing a vulnerable amino moiety had reacted with nitrites being a contaminant of an excipient. This review deals with the formation, toxicity, and mitigation of NDSRISs.
Collapse
Affiliation(s)
- U Holzgrabe
- Institute of Pharmacy and Food Chemistry, University of Wuerzburg Am Hubland, 97074 Wuerzburg, Germany.
| |
Collapse
|
10
|
Dispas A, Sacré PY, Ziemons E, Hubert P. Emerging analytical techniques for pharmaceutical quality control: Where are we in 2022? J Pharm Biomed Anal 2022; 221:115071. [PMID: 36179505 DOI: 10.1016/j.jpba.2022.115071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 09/05/2022] [Accepted: 09/20/2022] [Indexed: 12/19/2022]
Abstract
Quality control is a fundamental and critical activity in the pharmaceutical industry that guarantees the quality of medicines. QC analyses are currently performed using several well-known techniques, mainly liquid and gas chromatography. However, current trends are focused on the development of new techniques to reduce analysis time and cost, to improve the performances and decrease ecological footprint. In this context, analytical scientists developed and studied emerging technologies based on spectroscopy and chromatography. The present review aims to give an overview of the recent development of vibrational spectroscopy, supercritical fluid chromatography and multi-dimensional chromatography. Selected emerging techniques are discussed using SWOT analysis and published pharmaceutical QC applications are discussed.
Collapse
Affiliation(s)
- Amandine Dispas
- University of Liege (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium; University of Liege (ULiege), CIRM, Laboratory for the Analysis of Medicines, Liège, Belgium.
| | - Pierre-Yves Sacré
- University of Liege (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium
| | - Eric Ziemons
- University of Liege (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium
| | - Philippe Hubert
- University of Liege (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium
| |
Collapse
|
11
|
Pawar A, Pandita N. Application of the "Method Operable Design Region" (MODR) approach for the development of a UHPLC method for the assay and purity determination of risperidone in risperidone drug substance and other formulations. Biomed Chromatogr 2022; 36:e5433. [PMID: 35760414 DOI: 10.1002/bmc.5433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 06/22/2022] [Accepted: 06/22/2022] [Indexed: 11/08/2022]
Abstract
To understand the role of analytics in drug development, regulatory bodies also started using the approach of Quality by Design (QbD) during analytical method developments. The present study deals with the development of the "Method Operable Design Region" for assay and purity determination of risperidone in risperidone drug substance and formulations usingy UHPLC. Five different column chemistries, five different pH buffers, oven temperatures from 25 to 45°C, and different organic modifier composition, column lengths and flow rates were studied and statistically evaluated using Fusion QbD software. The final method parameters were selected by performing multivariable changes in a single run and evaluated using the Monte Carlo simulation approach. The uniqueness of this method is that it is mass compatible, a total of 10 peaks are separated within a short run time of 12.0 min and it uses a "Platforming approach", which means the use of a single method for testing the drug substance, different strengths of a drug product and different formulations. The same method can be also used for the determination of the preservative (benzoic acid) in risperidone 1 mg/ml oral solution. The use of the QbD approach is aligned with the US Pharmacopeia <1220>, BP supplementary chapter 2022 and the International Conference on Harmonization Q14 guidelines for life cycle management of analytical methods.
Collapse
Affiliation(s)
- Amit Pawar
- Department of Chemistry, Sunandan Divatia School of Science, NMIMS (Deemed-to-be) University, Mumbai, Maharashtra, India
| | - Nancy Pandita
- Department of Chemistry, Sunandan Divatia School of Science, NMIMS (Deemed-to-be) University, Mumbai, Maharashtra, India
| |
Collapse
|
12
|
Abd El-Hay SS, Elhenawee M, Maged K, Ibrahim AE. Cost-effective, green HPLC determination of losartan, valsartan and their nitrosodiethylamine impurity: application to pharmaceutical dosage forms. ROYAL SOCIETY OPEN SCIENCE 2022. [PMID: 35706671 DOI: 10.6084/m9.figshare.c.6011541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Angiotensin-converting enzyme inhibitors are one of the most widely used anti-hypertensive drugs which are used to reduce hypertension. In 2018, the United States Food and Drug Administration together with the European Medicine Agency declared the presence of carcinogenic nitrosamine impurities such as nitrosodiethylamine (NDEA) in some of the products, including valsartan (VLS) and losartan (LOS), and drugs' recall procedures were started. Thus, they should be controlled to be below the acceptable cancer risk level to ensure safety of the pharmaceutical products. Therefore, sensitive and reliable analytical methods were required for detection and quantitation of NDEA in bulk and finished drug products. Green analytical chemistry has received great interest to minimize the amount of organic solvents consumed without loss in chromatographic performance. A green and sensitive HPLC method was developed for the determination of NDEA in LOS and VLS using mobile phase of 0.02 M ammonium acetate adjusted to pH 7.2 and ethanol in gradient manner. Limits of detection and limits of quantification for NDEA were estimated to be 0.2 and 0.5 µg ml-1, respectively. The standardized limits of NDEA impurity in drug substances were set as 0.56 ppm, which indicates the feasibility of its determination by the proposed conventional method without need for expensive instrumentations (e.g. MS/MS detectors) that are not found in most pharmaceutical quality control laboratories.
Collapse
Affiliation(s)
- Soad S Abd El-Hay
- Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Magda Elhenawee
- Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Khaled Maged
- Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Sinai University, El-Areesh, Egypt
| | - Adel Ehab Ibrahim
- Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt
- Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman
| |
Collapse
|
13
|
Abd El-Hay SS, Elhenawee M, Maged K, Ibrahim AE. Cost-effective, green HPLC determination of losartan, valsartan and their nitrosodiethylamine impurity: application to pharmaceutical dosage forms. ROYAL SOCIETY OPEN SCIENCE 2022; 9:220250. [PMID: 35706671 PMCID: PMC9156911 DOI: 10.1098/rsos.220250] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Accepted: 05/09/2022] [Indexed: 05/03/2023]
Abstract
Angiotensin-converting enzyme inhibitors are one of the most widely used anti-hypertensive drugs which are used to reduce hypertension. In 2018, the United States Food and Drug Administration together with the European Medicine Agency declared the presence of carcinogenic nitrosamine impurities such as nitrosodiethylamine (NDEA) in some of the products, including valsartan (VLS) and losartan (LOS), and drugs' recall procedures were started. Thus, they should be controlled to be below the acceptable cancer risk level to ensure safety of the pharmaceutical products. Therefore, sensitive and reliable analytical methods were required for detection and quantitation of NDEA in bulk and finished drug products. Green analytical chemistry has received great interest to minimize the amount of organic solvents consumed without loss in chromatographic performance. A green and sensitive HPLC method was developed for the determination of NDEA in LOS and VLS using mobile phase of 0.02 M ammonium acetate adjusted to pH 7.2 and ethanol in gradient manner. Limits of detection and limits of quantification for NDEA were estimated to be 0.2 and 0.5 µg ml-1, respectively. The standardized limits of NDEA impurity in drug substances were set as 0.56 ppm, which indicates the feasibility of its determination by the proposed conventional method without need for expensive instrumentations (e.g. MS/MS detectors) that are not found in most pharmaceutical quality control laboratories.
Collapse
Affiliation(s)
- Soad S. Abd El-Hay
- Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Magda Elhenawee
- Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
| | - Khaled Maged
- Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Sinai University, El-Areesh, Egypt
| | - Adel Ehab Ibrahim
- Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt
- Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman
| |
Collapse
|
14
|
Schmidtsdorff S, Neumann J, Schmidt AH, Parr MK. Risk assessment for nitrosated pharmaceuticals: A future perspective in drug development. Arch Pharm (Weinheim) 2022; 355:e2100435. [PMID: 35088435 DOI: 10.1002/ardp.202100435] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Revised: 12/26/2021] [Accepted: 12/30/2021] [Indexed: 11/09/2022]
Abstract
Since June 2018, thousands of drug products from around the world had to be recalled due to the unexpected presence of nitrosamines (NAs). Starting with the pharmaceutical group of sartans, antidiabetic drugs, antihistamines, and antibiotics also became the subject of investigation. The occurrence of NAs has shown that pharmaceutical companies and regulatory agencies did not focus on these substances in the past during drug development. In this study, we incorporated a nitrosation assay procedure into high-resolution supercritical fluid chromatography (SFC)-mass spectrometry screening to test the potential of direct nitrosation of active pharmaceutical ingredients (APIs). The forced degradation study was performed with a four-fold molar excess of sodium nitrite, relative to the drug substance, at pH 3-4 for 4 h at 37°C. Chromatographic separation was performed on a porous graphitic carbon column by SFC. The mass analysis then focused on direct N-nitrosation or N-nitroso compounds (NOCs) formed after dealkylation. Substances (n = 67) from various pharmaceutical classes were evaluated and 49.3% of them formed NOCs, of which 21.2% have not yet been reported in the literature. In addition, for two APIs, which are known to form an unidentified NOC, the structure could be identified. A few substances also showed multiple NOCs and even N,N'-dinitroso-species. As NAs are carcinogens, they have to be eliminated or at least limited to prevent cancer in patients, who rely on these drugs. This study contributes a procedure that can be implemented in preapproval drug development and postapproval risk assessment to prevent unexpected findings in the future.
Collapse
Affiliation(s)
- Sebastian Schmidtsdorff
- Chromicent GmbH, Berlin, Germany.,Department of Biology, Chemistry, and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | - Jonas Neumann
- Chromicent GmbH, Berlin, Germany.,Department of Biology, Chemistry, and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | | | - Maria K Parr
- Department of Biology, Chemistry, and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany
| |
Collapse
|
15
|
Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets. J Pharm Biomed Anal 2022; 207:114417. [PMID: 34678556 DOI: 10.1016/j.jpba.2021.114417] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/16/2021] [Accepted: 10/01/2021] [Indexed: 02/06/2023]
Abstract
Analytical procedure development for quantifying 10 impurities in Tenofovir Alafenamide Fumarate (TAF) tablets was a challenge for analytical and formulation researchers. The aim of this paper was to develop a robust, regulatory-flexible, application-specific Ultra Performance Liquid Chromatography (UPLC) analytical procedure using the Analytical Lifecycle Management (ALM) and the Analytical Quality by Design (AQbD) for the estimation of the TAF tablets. In this work, the Analytical Target Profile (ATP) for the analytical procedure and the Critical Analytical Attributes (CAAs) were identified. Through the risk assessment studies, the high-risk analytical conditions were found, and they were screened and optimized by the Design of Experiment (DoE) to obtain the Design Space (DS) and identify the working point. The prediction intervals were used to examine the robustness of the analytical procedure. And the procedure performance qualification and the continued procedure performance verification were used to ensure routine application of analytical procedure. Finally, the 10 impurities were separated within 20 min by UPLC. The success of this study demonstrates the usefulness of using ALM and AQbD for analytical procedure development and provides a reference for the analytical procedure development for other drugs.
Collapse
|
16
|
Si-Hung L, Bamba T. Current state and future perspectives of supercritical fluid chromatography. Trends Analyt Chem 2022. [DOI: 10.1016/j.trac.2022.116550] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
17
|
Khater S, Ferguson P, Grand-Guillaume-Perrenoud A. Method development approaches for small-molecule analytes. SEP SCI TECHNOL 2022. [DOI: 10.1016/b978-0-323-88487-7.00005-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
18
|
Ferguson P, Hicks M. The state-of-the-art and future perspectives for SFC. SEP SCI TECHNOL 2022. [DOI: 10.1016/b978-0-323-88487-7.00013-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
19
|
Jambo H, Hubert P, Dispas A. Supercritical fluid chromatography for pharmaceutical quality control: Current challenges and perspectives. Trends Analyt Chem 2022. [DOI: 10.1016/j.trac.2021.116486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
20
|
Li BQ, Li XK, Lin Y, Li ZY, Zhang XZ, Feng N, Ma AJ, Chen CY, Tan LF. Development and validation of ultra-high performance supercritical fluid chromatography method for quantitative determination of six compounds in Guizhi Fuling capsule and tablet samples. J Sep Sci 2021; 44:3199-3207. [PMID: 34213832 DOI: 10.1002/jssc.202100181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 06/24/2021] [Accepted: 06/30/2021] [Indexed: 11/06/2022]
Abstract
A fast and simple ultra-high performance supercritical fluid chromatography method has been developed for the determination of six analytes, namely (paeonol, coumarin, cinnamic alcohol, cinnamic acid, paeoniflorin, and amygdalin) in Guizhi Fuling capsule and tablet samples. The influence of the key chromatographic parameters for the separation purposes was evaluated. The optimal column was Trefoil CEL1 column. The optimal mobile phase was a gradient mixture of carbon dioxide and methanol at flow rate of 1.0 mL/min. The back pressure of the system was set to 1.38 × 107 Pa and the temperature to 45°C. The six compounds were separated within 11 min by the proposed ultra-high performance supercritical fluid chromatography method with satisfactory resolution. Method validation confirmed that the procedure is accurate with the recovery rates from 87.04 to 104.30%, intraday precision values less than 4.81% and interday precision less than 5.22%, and linear with R2 higher than 0.9967. Therefore, this work provides a simple and novel method for the simultaneous analysis of six compounds in Guizhi Fuling capsule and tablet samples.
Collapse
Affiliation(s)
- Bao Qiong Li
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Xin Kang Li
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Yuan Lin
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Ze Ying Li
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Xiang-Zhi Zhang
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Na Feng
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Ai-Jun Ma
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Chao Yang Chen
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| | - Lin Fan Tan
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, P. R. China
| |
Collapse
|